BioSpace News Archive

Oculis, SA. (“Oculis”), a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (“EBAC”, NASDAQ: EBAC), a special purpose acquisition company (SPAC), today announced they have entered into a definitive business combination agreement.

Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for expanded labeling of a cardiac lead that taps into the heart’s natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy.

Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer.

Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients with major depressive disorder (MDD).

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference.

Galapagos NV announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 November2022.

Bavarian Nordic A/S announced the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

Iterum Therapeutics plc announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced certain preliminary financial data for the quarter ended September 30, 2022.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2022 financial results on Thursday, October 27, 2022, after the market close.